Publications by authors named "S Poletto"
Article Synopsis
- About 20% of prostate cancer patients have alterations in HRR genes like BRCA1/2, which are important biomarkers for treatment with PARP inhibitors like Olaparib, currently approved for metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations in Italy.
- A survey of 108 oncologists revealed that only 52.8% regularly test all metastatic prostate cancer patients for BRCA mutations, and many face challenges such as long wait times and unclear procedures.
- These obstacles hinder the effective implementation of genetic testing, limiting access to personalized PARP inhibitor treatment and highlighting the need for improved molecular testing processes in clinical settings.
Single-agent osimertinib has improved outcomes in EGFR-mutated lung cancer patients with brain metastases (BMs), but still, 40 % of them will experience an intracranial progression. We performed a systematic review to evaluate the role of brain radiotherapy upfront plus osimertinib. We evaluated articles comparing the use of osimertinib versus osimertinib plus brain radiotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Genomic-oriented oncology has enhanced the classification and treatment of tumors, yet challenges like genetic diversity and tumor cell adaptability hinder progress in curing cancer.
- Advances in organotypic cell cultures are changing how researchers study cancer, particularly with cancer organoids that complement genomic data, especially in lung cancer.
- Innovative systems like microfluidic mini-organs are being developed to replicate tumor environments, helping researchers test immunotherapies and advance personalized cancer treatment strategies.
Article Synopsis
- * A study analyzed 327 mCRPC patients on Enzalutamide or Abiraterone, finding that 9.8% had NED, which was associated with significantly poorer progression-free survival (PFS), disease control rate (DCR), and PSA response.
- * The negative impact of NED on patient outcomes was consistent regardless of treatment line, suggesting that assessing NED could help in making better treatment choices for mCRPC.
To develop and validatea novel neonatal non-invasive respiratory support device prototype designed to operate in low-resource settings. The device integrates a blower-based ventilator and a portable oxygen concentrator. A novel control algorithm was designed to achieve the desired fraction of inspired oxygen (FiO) while minimizing power consumption.
View Article and Find Full Text PDF